DOCSLIB.ORG

Linezolid Kabi July 2018 Linezolid Kabi

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Linezolid Kabi July 2018 Linezolid Kabi CMI for Linezolid Kabi July 2018 Linezolid Kabi Linezolid Consumer Medicine Information What is in this leaflet of medicine to treat depression, anxiety, panic attacks, obsessive-compulsive disorders This leaflet answers some common Before you are given or obesity (e.g. citalopram, questions about Linezolid Kabi. It Linezolid Kabi escitalopram, fluoxetine, does not contain all the available fluvoxamine, paroxetine, information. It does not take the When you must not be given it sertraline, duloxetine, place of talking to your doctor or sibutramine, venlafaxine, pharmacist. Linezolid Kabi must not be given desvenlafaxine) if you or your child: • tricyclic antidepressants, which All medicines have risks and • are allergic to linezolid or any of are medicines to treat benefits. Your doctor has weighed the other ingredients listed at depression (e.g. amitriptyline, the risks of you or your child taking the end of this leaflet. Linezolid Kabi against the benefits clomipramine, dothiepin, they expect it will have for you. Some of the symptoms of an doxepin, imipramine, allergic reaction may include: nortriptyline, trimipramine) shortness of breath, wheezing If you have any concerns about • some medicines to treat or difficulty breathing, swelling taking this medicine, ask your migraine (e.g. naratriptan, of the face, lips, tongue or other doctor or pharmacist. sumatriptan, zolmitriptan) parts of the body, rash, itching or hives on the skin. • pethidine, a medicine to treat Keep this leaflet. pain. You may need to read it again. • have uncontrolled high blood pressure • buspirone, a medicine to treat anxiety • have pheochromocytoma (a type of tumour of the adrenal What Linezolid Kabi is Before you start to be given it used for gland) • have thyrotoxicosis (an Tell the doctor if you or your Linezolid Kabi contains the active overactive thyroid gland) child: ingredient, linezolid. • have flushing or other • have allergies to any other symptoms caused by a medicines or substances, such Linezolid is an antibiotic (an agent carcinoid tumour as foods, preservatives or dyes used to destroy certain types of • are taking or have taken in the • are anaemic or have had any bacteria). It is used in the treatment last two weeks any medicine abnormal blood test results (e.g. of bacterial infections such as that is a monoamine oxidase low haemoglobin or platelets) pneumonia, skin infections or blood inhibitor (e.g. moclobemide, infections. • are diabetic (Linezolid Kabi phenelzine or tranylcypromine contains glucose) to treat depression or selegiline • have diarrhoea. Depending on the type of bacteria, to treat Parkinson's disease) you may be given additional medicines. • any cold or flu medicine Tell the doctor if you: containing pseudoephedrine • are pregnant or planning to Your doctor, however, may • adrenaline, a medicine used to become pregnant prescribe Linezolid Kabi for another treat severe allergic reactions purpose. • are breastfeeding or intend to • any other medicine that breastfeed. increases blood pressure (e.g. Ask your doctor if you have any noradrenaline, dopamine, If you are pregnant or questions about why Linezolid dobutamine) breastfeeding, the doctor may Kabi has been prescribed for decide not to prescribe Linezolid • are taking any medicine that is a you or your child. Kabi. serotonin re-uptake inhibitor (SSRI or SNRI), which are types This medicine is not addictive. Page 1 of 4 CMI for Linezolid Kabi July 2018 Talk to the doctor or pharmacist, • rifampicin, a medicine to treat of age is 10 mg/kg three times daily if you have any concerns about tuberculosis and some other (every 8 hours). you or your child being given infections Linezolid Kabi. • any medicine that could reduce These doses are given the levels of haemoglobin (the intravenously by a "drip" over a Taking other medicines pigment in red blood cells which period of 30 to 120 minutes. carries oxygen) or platelets Tell your doctor if you are taking (blood cells which help blood to Treatment is usually given every any other medicines, including clot). day for 10 to 14 days, but may medicines that you buy without a given for up to 28 days. prescription from a pharmacy, Ask the doctor or pharmacist if supermarket or health food you are not sure about this list of Ask the doctor if you want more shop. medicines. information about the dose of Linezolid Kabi and how it is In particular, tell the doctor if Also tell the doctor if your or given. you or your child have been your child's diet contains a lot of treated with or are taking: mature cheese, yeast extracts, If you are given too much • any medicine that inhibits meat extracts, soya bean (overdose) monoamine oxidase (e.g. extracts (e.g. soy sauce), Overdose is unlikely as treatment moclobemide, phenelzine or draught beers or wine. will be given by the doctor or nurse. tranylcypromine to treat The possible effects of overdose depression or selegiline to treat Linezolid may react with a are vomiting, tremors, Parkinson's disease) substance which is naturally unsteadiness or lack of present in these foods. • any cold or flu medicine coordination. containing pseudoephedrine • adrenaline, a medicine used to Tell the doctor or nurse treat severe allergic reactions How Linezolid Kabi is immediately if you or your child • any other medicine that given have any of these effects or if increases blood pressure (e.g. you or your child feel worse during or after treatment with noradrenaline, dopamine, It is recommended that treatment Linezolid Kabi. dobutamine) with Linezolid Kabi begin in a hospital. • are taking any medicine that is a serotonin re-uptake inhibitor (SSRI and SNRI), which are Linezolid Kabi will be given to you While you are given types of medicine to treat or your child by the doctor or nurse. Linezolid Kabi depression, anxiety, panic Linezolid Kabi is a liquid which is attacks, obsessive-compulsive Things you must do disorders or obesity (e.g. given by slow injection into the citalopram, escitalopram, blood (known as an intravenous infusion or "drip"). Follow all instructions given by fluoxetine, fluvoxamine, the doctor. paroxetine, sertraline, If you or your child is on dialysis, duloxetine, sibutramine, Linezolid Kabi should be given after In some cases, additional blood venlafaxine, desvenlafaxine) dialysis. tests may be required. • tricyclic antidepressants, which are medicines to treat You or your child may be changed As part of the treatment, you or depression (e.g. amitriptyline, from Linezolid Kabi to an oral your child may be given other clomipramine, dothiepin, preparation of linezolid to complete medicines including other doxepin, imipramine, your course of treatment. antibiotics. It is important to keep nortriptyline, trimipramine) taking these medicines as well as How much is given Linezolid Kabi unless you are told • some medicines to treat otherwise by your doctor or migraine (e.g. naratriptan, The recommended dose for adults pharmacist. sumatriptan, zolmitriptan) and adolescents 12 years and • pethidine, a medicine to treat older is 600 mg twice daily (every It is important to tell the doctor if pain. 12 hours). you develop diarrhoea during or • buspirone, a medicine to treat after treatment with Linezolid anxiety The recommended doses for Kabi. Do this even if it occurs babies and children up to 12 years several weeks after Linezolid Kabi has been stopped. Page 2 of 4 CMI for Linezolid Kabi July 2018 This is because Linezolid Kabi may given the next dose of Linezolid Do not take any medicine to treat react with a substance which is Kabi if you notice any of the diarrhoea without first checking naturally present in these foods. following: with the doctor. • skin reactions (hives, rash or If you or your child develop a itching) Diarrhoea may be caused by a throbbing headache after eating, serious condition affecting the tell your doctor or health care • visual disturbances or bowel. You or your child may need professional. numbness or weakness of the urgent medical care. arms and legs (rare side effects that have been primarily reported in patients treated for If you or your child gets a sore Side Effects white mouth or tongue during or longer than 28 days) soon after treatment with • tiredness, headaches, being Tell the doctor or pharmacist as Linezolid Kabi tell your doctor. short of breath when exercising, soon as possible if you or your dizziness, looking pale, fever child do not feel well while you Tell the doctor if you or your and chills, sore throat or are taking Linezolid Kabi. child gets vaginal itching or bruising (these symptoms may discharge. indicate a decrease in the level This medicine helps most people, of your blood cells) but it may have unwanted side This may mean you or your child effects in a few people. All • sweating, feeling drunk and have a fungal infection called medicines can have side effects. If dizzy, muscle twitching, fever thrush. they occur, most are likely to be and shivering, confusion. minor and temporary. However, These may be symptoms of the Sometimes the use of Linezolid some may be serious and need serotonin syndrome, which is a Kabi allows fungi to grow which medical attention. rare but serious side effect. causes the symptoms described above. Linezolid Kabi does not Do not be alarmed by the If any of the following happen, work against fungi. following lists of side effects. tell your or your child's doctor immediately or go to Accident Things you must not do You or your child may not and Emergency at your nearest hospital: Do not start taking any other experience any of them. medicines, prescription or not, • seizure without first telling your doctor Ask the doctor or pharmacist to • shortness of breath answer any questions you may or pharmacist. • wheezing or difficulty breathing have. Do not give your child any other • swelling of the face, lips, tongue medicines, prescription or While taking it or other parts of the body purchased from a health food • rash, severe itching or hives or shop, pharmacy or supermarket Tell the doctor or pharmacist if blisters on the skin.
Load more

Recommended publications
  • Antibiotic Practice Change to Curtail Linezolid Use in Pediatric Hospitalized Patients in Hawai‘I with Uncomplicated Skin and Soft Tissue Infections
    Antibiotic Practice Change to Curtail Linezolid Use in Pediatric Hospitalized Patients in Hawai‘i with Uncomplicated Skin and Soft Tissue Infections Cheryl Okado MD and Tori Teramae BS Abstract MRSA coverage, clindamycin became a widely-used antibi- otic for treating uncomplicated SSTIs in children. Following Antimicrobial resistance affects health care providers’ choice of antibiotics increasing clindamycin use, increasing clindamycin resistance in the treatment of skin and soft tissue infections (SSTIs). Based on local was soon noted, particularly in MRSA isolates.2 Prior to 2010, antibiotic susceptibility data showing high clindamycin resistance and high MRSA predominance appeared to peak, and since then it has MRSA prevalence, a change in antibiotic regimen for children hospitalized for 3 uncomplicated SSTIs was instituted in an attempt to curb the use of linezolid. been decreasing. The prevalence of clindamycin-resistant GAS A retrospective chart review was performed on 278 pediatric patients with has been known to vary with time and location with US rates uncomplicated SSTIs hospitalized at Kapi‘olani Medical Center for Women ranging from 4%-41% since the early 2000s.4 and Children in Hawai‘i from May 2014 to April 2015 and November 2015 to October 2016. Data consisted of 12 months of baseline data and 12 In Hawai‘i, methicillin and clindamycin resistance patterns of months of data post-implementation of an antibiotic combination regimen of SA initially followed similar increasing trends. Antibiograms 2 widely-used antibiotics: high-dose cefazolin and high-dose clindamycin. at Hawai‘i’s children’s hospital, Kapi‘olani Medical Center for Practitioners were encouraged to use cefazolin alone if clinical suspicion was high for single-organism infection with group A streptococcus.
    [Show full text]
  • Drug News Nov Issue 25
    D r u g N e w s 藥 物 情 報 Issue No. 25 : November 2011 This is a monthly digest of local and overseas drug safety news and information released in the previous month. For the latest news and information, please refer to public announcements or the website of the Drug Office of the Department of Health (http://www.drugoffice.gov.hk). Safety Update US: Updated information about drug Canada and FDA released similar alerts on the interaction of Zyvox (linezolid) and interaction between methylene blue and serotonin Methylene Blue with serotonergic reuptake inhibitors. At the same time, FDA also released alert on the interaction between linezolid psychiatric medications and serotonin reuptake inhibitors. The news had 20 October 2011 – The Food and Drug been reported in Issue No. 17 and 22 of Drug News Administration (FDA) provided additional respectively. In addition, the Department of Health information about the possible serotonin syndrome (DH) issued press statement on 18 February 2011 in patients taking serotonergic psychiatric and letters were also sent to healthcare professionals medications and linezolid/ methylene blue. It was in February 2011 and July 2011. found that not all serotonergic psychiatric drugs had The product certificate holders of the an equal capacity to cause serotonin syndrome with pharmaceutical products containing methylene blue, use of linezolid/ methylene blue. According to the linezolid and serotonergic psychiatric medications FDA's Adverse Event Reporting System (AERS), have been requested to update the sales pack and/or most cases of serotonin syndrome with linezolid or package insert of these products to include methylene blue occurred in patients taking specific information about the potential drug interactions.
    [Show full text]
  • Treatment of Drug-Resistant Tuberculosis an Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R
    AMERICAN THORACIC SOCIETY DOCUMENTS Treatment of Drug-Resistant Tuberculosis An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R. Mase, Giovanni Battista Migliori, Giovanni Sotgiu, Graham H. Bothamley, Jan L. Brozek, Adithya Cattamanchi, J. Peter Cegielski, Lisa Chen, Charles L. Daley, Tracy L. Dalton, Raquel Duarte, Federica Fregonese, C. Robert Horsburgh, Jr., Faiz Ahmad Khan, Fayez Kheir, Zhiyi Lan, Alfred Lardizabal, Michael Lauzardo, Joan M. Mangan, Suzanne M. Marks, Lindsay McKenna, Dick Menzies, Carole D. Mitnick, Diana M. Nilsen, Farah Parvez, Charles A. Peloquin, Ann Raftery, H. Simon Schaaf, Neha S. Shah, Jeffrey R. Starke, John W. Wilson, Jonathan M. Wortham, Terence Chorba, and Barbara Seaworth; on behalf of the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America THIS OFFICIAL CLINICAL PRACTICE GUIDELINE WAS APPROVED BY THE AMERICAN THORACIC SOCIETY, THE EUROPEAN RESPIRATORY SOCIETY, AND THE INFECTIOUS DISEASES SOCIETY OF AMERICA SEPTEMBER 2019, AND WAS CLEARED BY THE U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION SEPTEMBER 2019 Background: The American Thoracic Society, U.S. Centers for was judged to be very low, because the data came Disease Control and Prevention, European Respiratory Society, and from observational studies with significant loss to follow-up Infectious Diseases Society of America jointly sponsored this new and imbalance in background regimens between comparator practice guideline on the treatment of drug-resistant tuberculosis groups. Good practices in the management of MDR-TB are (DR-TB). The document includes recommendations on the described. On the basis of the evidence review, a clinical strategy treatment of multidrug-resistant TB (MDR-TB) as well as tool for building a treatment regimen for MDR-TB is also isoniazid-resistant but rifampin-susceptible TB.
    [Show full text]
  • Frequently Asked Questions on The
    Frequently asked questions on the WHO treatment guidelines for isoniazid-resistant tuberculosis Version: 24 April 2018 The advice in this document has been prepared by the Global TB Programme of the World Health Organization (WHO) and is to be read alongside the WHO treatment guidelines for isoniazid-resistant tuberculosis and its online annexes. See Further reading ​ ​ at end for additional resources. Who are the new WHO treatment guidelines for isoniazid-resistant tuberculosis intended for ? ​ ​ The WHO treatment guidelines for isoniazid-resistant tuberculosis are targeted at health care ​ professionals (doctors, nurses) and other staff involved in TB care in both low and high resource settings. The possibility of drug-resistant disease now needs to be entertained whenever treating TB patients. These guidelines provide technical detail which is helpful in making the best-informed decision in clinical practice and programme management. The answers to the frequently asked questions (FAQ) in this document intend to help implementers with common, practical issues that arise when adopting the new guidance. This document complements the WHO guidelines by elaborating further on certain aspects of ​ implementation that were beyond the scope of the guideline itself. What are the main recommendations of these new guidelines ? The new guidelines recommend that patients with confirmed isoniazid-resistant and rifampicin susceptible tuberculosis (abbreviated to Hr-TB) are treated for 6 months with a regimen composed of ​ ​ rifampicin (R), ethambutol (E), pyrazinamide (Z) and levofloxacin (Lfx). The exclusion of rifampicin resistance ahead of start of this regimen is critical. It is further recommended not to add streptomycin (S) or other injectable agents to the treatment regimen.
    [Show full text]
  • Medications to Be Avoided Or Used with Caution in Parkinson's Disease
    Medications To Be Avoided Or Used With Caution in Parkinson’s Disease This medication list is not intended to be complete and additional brand names may be found for each medication. Every patient is different and you may need to take one of these medications despite caution against it. Please discuss your particular situation with your physician and do not stop any medication that you are currently taking without first seeking advice from your physician. Most medications should be tapered off and not stopped suddenly. Although you may not be taking these medications at home, one of these medications may be introduced while hospitalized. If a hospitalization is planned, please have your neurologist contact your treating physician in the hospital to advise which medications should be avoided. Medications to be avoided or used with caution in combination with Selegiline HCL (Eldepryl®, Deprenyl®, Zelapar®), Rasagiline (Azilect®) and Safinamide (Xadago®) Medication Type Medication Name Brand Name Narcotics/Analgesics Meperidine Demerol® Tramadol Ultram® Methadone Dolophine® Propoxyphene Darvon® Antidepressants St. John’s Wort Several Brands Muscle Relaxants Cyclobenzaprine Flexeril® Cough Suppressants Dextromethorphan Robitussin® products, other brands — found as an ingredient in various cough and cold medications Decongestants/Stimulants Pseudoephedrine Sudafed® products, other Phenylephrine brands — found as an ingredient Ephedrine in various cold and allergy medications Other medications Linezolid (antibiotic) Zyvox® that inhibit Monoamine oxidase Phenelzine Nardil® Tranylcypromine Parnate® Isocarboxazid Marplan® Note: Additional medications are cautioned against in people taking Monoamine oxidase inhibitors (MAOI), including other opioids (beyond what is mentioned in the chart above), most classes of antidepressants and other stimulants (beyond what is mentioned in the chart above).
    [Show full text]
  • Serotonin Syndrome Due to Co-Administration of Linezolid and Methadone
    Le Infezioni in Medicina, n. 3, 263-266, 2017 CASE REPORT 263 Serotonin syndrome due to co-administration of linezolid and methadone Antonio Mastroianni1, Gianfranco Ravaglia2 1U.O. Malattie Infettive, Presidio Ospedaliero, “G.B. Morgagni - L. Pierantoni”, Forlì, Italy; 2U.O. Farmacia, Presidio Ospedaliero “G.B. Morgagni - L. Pierantoni”, Forlì, Italy SUMMARY Serotonin syndrome (SS), a potentially life-threatening verity from mild to life-threatening. To our knowledge, adverse drug reaction caused by excessive serotoner- we present the first reported case of SS associated with gic agonism in central and peripheral nervous system linezolid and methadone with a brief review of the lit- serotonergic receptors, may be caused by a single drug erature. or a combination of drugs with serotonergic activity. The syndrome results in a variety of mental, autonom- Keywords: serotonin syndrome, linezolid, methadone, ic and neuromuscular changes, which can range in se- methicillin-resistant Staphylococcus aureus. n INTRODUCTION methadone. This serious adverse interaction be- tween linezolid and methadone inducing SS was erotonin syndrome (SS) is a toxic state caused reported in a drug-addict HIV-positive man with Smainly by excessive serotonergic activity in sepsis, osteomyelitis and multiple muscle abscess- the nervous system, nearly always caused by a es and metastatic skin abscesses caused by meth- drug interaction involving two or more “seroto- icillin-resistant Staphylococcus aureus (MRSA), un- nergic” drugs [1]. These include serotonin pre- der combined antibiotic treatment. cursors, serotonin agonists, serotonin releasers, serotonin reuptake inhibitors, monoaminoxidase inhibitors (MAOIs) and some herbal medicines. n CASE REPORT Linezolid is a weak, nonselective, reversible in- hibitor of MAOIs, and potentially may interact A 39-year-old drug-addict male was admitted to with MAOIs and adrenergic and serotonergic our department with fever (up to 39.5°C) and a agents.
    [Show full text]
  • ZYVOX (Linezolid) Injection (Linezolid) Tablets (Linezolid) for Oral Suspension
    ® ZYVOX (linezolid) injection (linezolid) tablets (linezolid) for oral suspension To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX formulations and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION ZYVOX I.V. Injection, ZYVOX Tablets, and ZYVOX for Oral Suspension contain linezolid, which is a synthetic antibacterial agent of the oxazolidinone class. The chemical name for linezolid is (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl] methyl]-acetamide. The empirical formula is C16H20FN3O4. Its molecular weight is 337.35, and its chemical structure is represented below: O O O N N O C C H N 3 F H ZYVOX I.V. Injection is supplied as a ready-to-use sterile isotonic solution for intravenous infusion. Each mL contains 2 mg of linezolid. Inactive ingredients are sodium citrate, citric acid, and dextrose in an aqueous vehicle for intravenous administration. The sodium (Na+) content is 0.38 mg/mL (5 mEq per 300-mL bag; 3.3 mEq per 200-mL bag; and 1.7 mEq per 100-mL bag). ZYVOX Tablets for oral administration contain 400 mg or 600 mg linezolid as film-coated compressed tablets. Inactive ingredients are corn starch, microcrystalline cellulose, hydroxypropylcellulose, sodium starch glycolate, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide, and carnauba wax. The sodium (Na+) content is 1.95 mg per 400-mg tablet and 2.92 mg per 600-mg tablet (0.1 mEq per tablet, regardless of strength).
    [Show full text]
  • Tuberculosis Drug Information Guide, 2Nd Edition
    Tuberculosis Drug Information Guide 2ND EDITION Edmund G. Brown Jr, Governor STATE OF CALIFORNIA Diana S. Dooley, Secretary CALIFORNIA HEALTH & HUMAN SERVICES AGENCY Ron Chapman, MD, MPH, Director DEPARTMENT OF PUBLIC HEALTH Tuberculosis Drug Information Guide 2ND EDITION Edmund G. Brown Jr, Governor STATE OF CALIFORNIA Diana S. Dooley, Secretary CALIFORNIA HEALTH & HUMAN SERVICES AGENCY Ron Chapman, MD, MPH, Director DEPARTMENT OF PUBLIC HEALTH DrugInfo_2ndEd_v9.indd 3 12/5/12 3:55 PM Tuberculosis Drug Information Guide, 2nd edition was created through a collaboration of the Curry International Tuberculosis Center (CITC) and the State of California Department of Public Health, Tuberculosis Control Branch (CDPH). CITC is a project of the University of California, San Francisco, funded by the Centers for Disease Control and Prevention (CDC). The development of this Guide was funded through CDC Cooperative Agreement U52 CCU 900454. Permission is granted for nonprofit educational use and library duplication and distribution. Suggested citation: Curry International Tuberculosis Center and California Department of Public Health, 2012: Tuberculosis Drug Information Guide, 2nd edition. This publication is available on the CITC website: http://www.currytbcenter.ucsf.edu/ tbdruginfo/ Design: Edi Berton Design DrugInfo_2ndEd_v9.indd 4 12/5/12 3:55 PM Contributors Acknowledgments Ann M. Loeffler, MD John S. Bradley, MD Pediatric Infectious Diseases Attending and Director of Pediatric Rady Children’s Hospital San Diego, San Diego, California Hospitalists at Randall Children’s Hospital at Legacy Emanuel, Daniel Deck, Pharm.D. Portland, Oregon Department of Pharmaceutical Services, Pediatric Tuberculosis Consultant, San Francisco General Hospital, California Curry International Tuberculosis Center, San Francisco, California David Forinash, RPh Randall Children’s Hospital at Legacy Emanuel, Portland, Oregon Charles A.
    [Show full text]
  • Formulary and Program Updates Effective 8/1/18
    Formulary and Program Updates Effective 8/1/18 Pharmacy & Therapeutics Committee Meeting May 22, 2018 6:30 – 8:00 PM Role Call VOTING MEMBERS NON-VOTING MEMBERS • David Konanc, MD • Carl Antolick III, PharmD • Matthew K. Flynn, MD • Tracy Linton, MPH • Jennifer Burch, PharmD • Dee Jones • Peter Robie, MD • Lucy Barreto, DDS, MHA • Tony Gurley, RPh, JD • Renee Jarnigan, RPh • Michael Spiritos, MD • Stephanie Morrison, PharmD • John B. Anderson, MD, MPH • John Engemann, MD • Joseph Shanahan, MD 2 Ethics Awareness & Conflict of Interest Reminder In accordance with the NC State Health Plan for Teachers and State Employees’ ethics policy, it is the duty of every member of the Pharmacy & Therapeutics Committee, whether serving in a vote casting or advisory capacity, to avoid both conflicts of interest and appearances of conflict. Does any Committee member have any known conflict of interest or the appearance of any conflict with respect to any manufacturers of any medication to be discussed at today’s meeting? Or, if during the course of the evaluation process if you identify a conflict of interest or the appearance of a conflict. If so, please identify the conflict or appearance of conflict and refrain from any undue participation in the particular matter involved. 3 Minutes from Previous Committee Meeting • Instead of having the Secretary read the minutes, copies have been distributed for your review. • They are located just after the conflict of interest statement in the P&T Booklet that was emailed out. • Are there any additions or corrections to the minutes? • If not, the minutes will stand approved as is.
    [Show full text]
  • Adverse Effects of Psychotropic Medication
    Adverse effects of psychotropic medication RACHEL BROWN CLINICAL LEAD PHARMACIST – CAMHS, MEDICINES ADVICE AND CLINICAL EFFECTIVENESS OXFORD HEALTH NHS FOUNDATION TRUST Antipsychotic-induced hyperprolactinaemia Serotonin Syndrome Antipsychotic-induced hyperprolactinaemia Hyperprolactinaemia with APs 4 Dopamine inhibits prolactin release via D2 stimulation; serotonin promotes prolactin release via 5HT2A stimulation All antipsychotics are D2 antagonists → block the effect of DA → prolactin levels rise In the case of (most) second generation (atypical) there is simultaneous inhibition of 5HT2A receptors so serotonin can no longer stimulate prolactin release – theoretically cancel effects out Low risk antipsychotics High risk antipsychotics Aripiprazole Amisulpride Quetiapine Risperidone Lurasidone Paliperidone Clozapine Sulpiride Asenapine “Typical” / first generation antipsychotics Olanzapine? Causes of elevated prolactin 6 Physiological causes: Pharmacological causes Pathological causes • Pregnancy • Lactation • Antipsychotics • Prolactinoma • Stress (PRL levels of up to about 700 • Antidepressants* • Other pituitary or hypothalamic mU/L in men and 900 mU/L in • Opiates tumours or lesions women) • Peripheral dopamine receptor blockers • Hypothyroidism • Circadian variation (levels are e.g. metoclopramide, domperidone • Polycystic ovary syndrome highest in morning) • Antihypertensives e.g. calcium channel • Severe renal or liver disease • Macroprolactin (large molecular blockers, methyldopa aggregates lacking biological • H2 antagonists
    [Show full text]
  • Linezolid (Zyvox®)
    Linezolid (Zyvox®) IV and PO Only Use requires formal ID Consult Activity: Coverage against Staphylococcus aureus (MSSA and MRSA), Streptococcus pneumoniae, VRE Criteria for Use: • Vancomycin (VAN) MIC ≥ 2 mg/L in MRSA pneumonia • Patient with allergy to beta-lactams/vancomycin and organism resistant to other antimicrobials • Significant VRE infections (i.e. isolated from a sterile site: blood, abscess) • Infections due to MRSA in patient with well documented intolerance to VAN (NOTE: Red man syndrome is not a serious intolerance to VAN) Formal ID consult for use in osteomyelitis or complicated skin and soft tissue infection and all indications that are not listed above Unacceptable Uses: • Empiric use when VRE has not been cultured or documented • Uncomplicated urinary tract infection • Positive respiratory culture for VRE • VRE colonization Dosing in Adults: • Standard dose: 600 mg PO or IV Q12H In patients tolerating PO medications, should be given orally Oral formulation is completely absorbed and has 100% availability • No renal or hepatic dose adjustment Monitoring: • CBC at baseline and weekly (MONITOR platelets at baseline and weekly) Considerations for Use: • Caution in patients with thrombocytopenia. 3 percent of patients were noted to have a platelet decrease <75% of baseline or lower limit of normal in controlled trials (therapy <28 days, most < 21 days). Thrombocytopenia is reversible upon discontinuation and is correlated with duration • Linezolid is a weak MAOI. Use in caution with decongestants (i.e. pseudoephedrine) and
    [Show full text]
  • UWHC Guidelines for the Use of Linezolid (Zyvox )
    UWHC Guidelines for the Use of Linezolid (Zyvox®) Guidelines developed by UWHC Center for Drug Policy (CDP) Authors: Deborah Dunham, MA, RPh; Sarah E. Bland, RPh Coordination: Lee Vermeulen, MS, RPh, Director, CDP Reviewed by: William Craig, MD; Barry Fox, MD; Dennis Maki, MD; George Mejicano, MD; Carol A. Spiegel, PhD Originally Approved by P&T Committee: July 2000 Last Revised: August 2009 Next Scheduled For Review: August 2011 A. Background Because of the increase in multi-drug-resistant strains of gram-positive bacteria, the development of new and novel-acting antimicrobial agents is at the forefront of pharmaceutical research. Currently, the prevalence of methicillin-resistant staphylococci (MRSA) and vancomycin-resistant enterococci (VRE) is a major clinical problem. Linezolid (Zyvox®-Pfizer) is an antimicrobial agent of the oxazolidinone class that possesses a wide spectrum of activity against gram-positive organisms, including MRSA and VRE. Because of linezolid’s novel mechanism of action, cross-resistance with other antimicrobial agents is not expected. Linezolid is therefore a viable option for certain types of infectious disease. B. Appropriate Indications Linezolid has limited therapeutic applications at UW Hospital and Clinics. Appropriate use of linezolid will require a culture/susceptibility test with positive identification of an organism that demonstrates definitive resistance to all other possible antimicrobial agents. Based on the potential for bacterial resistance associated with the use of linezolid, the UW Pharmacy and Therapeutics Committee has approved its use in the following conditions: 1.0 Vancomycin-resistant Enterococcus faecium infections (not colonization), including those with concurrent bacteremia. 2.0 Methicillin-resistant S aureus infections (MRSA) in patients unable to tolerate vancomycin therapy or with serious pneumonia with MRSA.
    [Show full text]